Growth Hormone Axis

What the growth hormone axis is

The growth hormone axis — formally the hypothalamic–pituitary–somatotropic axis — is the chain of command that decides how much a child grows and how an adult body partitions fuel between fat, muscle, and bone. It has three anatomical levels and one circulating messenger that does most of the actual work:

• The hypothalamus sends two opposing signals down to the pituitary through the portal blood: growth-hormone-releasing hormone (GHRH), which says "fire," and somatostatin (also called GHIH), which says "hold." The balance between these two sets the timing and size of each pulse.
• The anterior pituitary contains somatotrophs — the most numerous hormone-producing cell in the gland, roughly half of all anterior pituitary cells — which store and release growth hormone (GH, somatotropin), a 191-amino-acid protein.
• The liver is the main downstream factory. GH binding to hepatic GH receptors switches on production of insulin-like growth factor 1 (IGF-1), which circulates bound to IGFBP-3 and the acid-labile subunit (ALS) and carries out most of the axis's growth-promoting effects in distant tissues.

The defining feature of this axis is that it is pulsatile. GH is not dribbled out at a constant rate; it is fired in discrete bursts, with near-undetectable levels in between. This pulse pattern, not just the total amount, is itself a signal — the liver and other tissues read the rhythm.

How a pulse fires: GHRH, somatostatin, and ghrelin

At any given moment the somatotroph is listening to a tug-of-war. Somatostatin sets the tonic brake; when its tone is high, GH stays suppressed regardless of other signals. A pulse begins when somatostatin tone falls and a wave of GHRH arrives, binding a Gs-protein-coupled receptor that raises cyclic AMP and triggers exocytosis of stored GH granules. A third player, ghrelin — the "hunger hormone" from the stomach — acts on the GH secretagogue receptor (GHS-R) to amplify the pulse, which is why GH rises during fasting.

Because GH has a plasma half-life of only about 15-20 minutes, each spike is brief: levels can jump from under 1 microgram per liter to 10-30 micrograms per liter at the peak of a large nocturnal burst, then collapse back to baseline within an hour. Healthy adults fire roughly 6-10 secretory episodes per 24 hours, but the single dominant pulse is tied to the onset of slow-wave (deep, stage N3) sleep, typically within the first one to two hours of falling asleep. That nocturnal pulse can account for the majority of the day's total GH output, which is the physiological reality behind the folk wisdom that children grow in their sleep.

This pulsatility creates a hard clinical problem: a single random GH blood level is nearly worthless, because it might be caught at a peak or a trough that differ by more than an order of magnitude. Clinicians therefore measure the steady downstream signal — IGF-1 — or use dynamic testing: a stimulation test (insulin-induced hypoglycemia, glucagon, or macimorelin) to prove the axis can fire when deficiency is suspected, and a suppression test (oral glucose load) to prove it cannot be switched off when excess is suspected.

The liver relay: IGF-1 does the building

GH itself has two faces. Its direct effects are largely anti-insulin and catabolic toward fat: it stimulates lipolysis (freeing fatty acids for fuel), reduces glucose uptake by muscle and fat, and promotes hepatic glucose output. This is why GH is sometimes called a "diabetogenic" hormone and why chronic excess produces insulin resistance.

But the famous growth-promoting, anabolic effects are mostly indirect, carried out by IGF-1. When GH binds hepatocyte receptors, the liver releases IGF-1 into the blood, where carrier proteins extend its half-life to many hours and smooth the GH pulses into a stable daily level. IGF-1 then travels to the epiphyseal growth plates of the long bones, where — together with locally produced IGF-1 — it drives chondrocytes in the proliferative zone to divide and enlarge. That cartilage scaffold is then replaced by bone in a process called endochondral ossification, lengthening the bone. IGF-1 also promotes protein synthesis and lean mass in muscle and supports many other tissues.

The growth plate is the key to a confusing clinical fact. The plate stays open through childhood and adolescence, then sex steroids fuse it shut at the end of puberty, permanently ending height gain. After fusion, GH and IGF-1 can no longer make a person taller — they can only thicken bone and enlarge soft tissue. That is exactly why the same hormonal excess produces gigantism (extreme height) before fusion and acromegaly (broadening of hands, feet, jaw, and brow) after it.

Negative feedback: how the axis shuts itself off

The growth hormone axis is a textbook negative-feedback loop with two nested brakes. In long-loop feedback, IGF-1 from the liver travels back up to the hypothalamus and pituitary, where it stimulates somatostatin release and suppresses both GHRH and GH. In short-loop feedback, GH itself raises somatostatin tone, so every pulse is inherently self-limiting and sows the seeds of its own shutdown.

Metabolic state layers on top of this. High blood glucose and high free fatty acids suppress GH, whereas low glucose, fasting, exercise, deep sleep, and ghrelin all stimulate it. The net result of tonic somatostatin braking interrupted by episodic GHRH/ghrelin drive is precisely the spiky, mostly nocturnal pattern that defines the axis. When a GH-secreting tumor breaks this loop, the hallmark on testing is that an oral glucose load — which should crush GH — fails to suppress it below about 1 microgram per liter.

Normal values and thresholds clinicians use

• Random GH: wide range, undetectable to ~10-30 µg/L at peak; not interpretable in isolation.
• IGF-1: reported against age- and sex-matched reference ranges; it falls steadily across adult life, so a "normal" value for a 70-year-old would be low for a teenager.
• OGTT suppression (acromegaly): GH should fall below ~0.4-1 µg/L after 75 g oral glucose; failure to suppress supports the diagnosis.
• Stimulation cut-offs (deficiency): a peak GH below a test-specific threshold (often cited around 3-5 µg/L on insulin tolerance or glucagon testing) supports adult GH deficiency.
• GH pulse frequency: ~6-10 secretory bursts per 24 hours, dominated by the early-sleep pulse.

When the axis breaks: the spectrum of disease

Disorders of the growth hormone axis line up neatly along a too-little / too-much spectrum, and the clinical picture depends heavily on whether the growth plates are still open.

State	GH / IGF-1	Typical cause	Hallmark features	Key management
GH deficiency (child)	Low GH, low IGF-1	Congenital, pituitary tumor, radiation, idiopathic	Slow growth velocity, short stature, delayed bone age, increased fat	Daily recombinant GH injections; earlier start = better adult height
GH deficiency (adult)	Low (provocative test needed)	Pituitary surgery/radiation, trauma, tumor	Low lean mass, central fat gain, low bone density, fatigue, dyslipidemia	GH replacement titrated to IGF-1 and symptoms
Acromegaly (adult excess)	High GH, high IGF-1	GH-secreting pituitary adenoma (somatotroph tumor)	Enlarged hands/feet/jaw/brow, sweating, arthropathy, insulin resistance, OSA	Surgery; somatostatin analogues (octreotide, lanreotide); pegvisomant (GH-receptor blocker)
Gigantism (childhood excess)	High GH, high IGF-1	GH-secreting adenoma before growth-plate fusion	Extreme height, rapid growth, plus acromegalic features	Same as acromegaly; urgent because plates are still open
Laron syndrome	High GH, very low IGF-1	GH-receptor mutation (GH resistance)	Severe short stature despite high GH; IGF-1 cannot be made	Recombinant IGF-1 (mecasermin), not GH

Acromegaly is the most instructive disease here. A benign somatotroph adenoma ignores feedback and pours out GH continuously; because adult growth plates are fused, bone thickens rather than lengthens. The face coarsens, the brow and jaw protrude, hands and feet enlarge so rings and shoes no longer fit, and soft-tissue swelling causes carpal tunnel syndrome and obstructive sleep apnea. Untreated, the chronic insulin resistance, hypertension, and cardiomyopathy meaningfully shorten life. Because the changes creep on over years, the diagnosis is often made by an observant clinician comparing old photographs — or made first by a dentist noticing the jaw.

Laron syndrome is the mirror image and a beautiful confirmation of the mechanism: these patients have high GH but cannot respond to it because their GH receptor is broken, so they make almost no IGF-1 and remain severely short. Treating them with GH is useless; they need IGF-1 directly. Intriguingly, the same IGF-1 deficiency appears to protect this population from cancer and diabetes, which has made the axis a focus of aging research.

Clinical and everyday correlations

• Sleep and growth. Because the dominant pulse is tied to slow-wave sleep, chronic sleep deprivation and untreated sleep apnea blunt GH secretion — a real link between sleep quality and body composition.
• Exercise and fasting. Both transiently raise GH, part of the metabolic switch toward burning fat and sparing protein during energy stress.
• Doping. GH is abused in sport for its anabolic and lipolytic effects, but it is hard to detect because of its short half-life and pulsatility; antidoping tests therefore look at IGF-1 and collagen markers, not GH itself.
• Diabetes interaction. GH is counter-regulatory and anti-insulin, so acromegaly commonly unmasks diabetes, and poorly controlled diabetes can paradoxically lower IGF-1.
• Aging (somatopause). GH and IGF-1 decline progressively with age, contributing to the loss of lean mass and bone density — but trials of GH replacement in healthy older adults show side effects without clear benefit, so it is not recommended as an anti-aging therapy.

This article is educational and is not medical advice. Diagnosis and treatment of growth and pituitary disorders require evaluation by a qualified clinician.